<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00336843</url>
  </required_header>
  <id_info>
    <org_study_id>AMC 2005-276</org_study_id>
    <nct_id>NCT00336843</nct_id>
  </id_info>
  <brief_title>Zevalin Plus BuCyE High-dose Therapy in B-cell Non-Hodgkin's Lymphoma</brief_title>
  <official_title>Combining 90Y-ibritumomab Tiuxetan With High-dose Chemotherapy of BuCyE and Autologous Stem Cell Transplantation in Patients With B-cell Non-Hodgkin's Lymphoma - an Open-labeled Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Schering-Plough</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In order to improve the clinical result of high-dose chemotherapy and autologous stem cell
      transplantation for B-cell non-Hodgkin's lymphoma, Zevalin will be added to the conditioning
      regimen. Investigators expect this radioimmunotherapy of Zevalin plus busulfan,
      cyclophosphamide and etoposide regimen will improve survival of relapsed or poor-risk B-cell
      non-Hodgkin's lymphoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Title: Combining 90Y-Ibritumomab tiuxetan (Zevalin) with high-dose chemotherapy of BuCyE and
      autologous stem cell transplantation in patients with relapsed, refractory, or high-risk
      B-cell non-Hodgkin's lymphoma - an open-labeled phase II study.

      Study design: Prospective, multicenter, open-labeled, phase II trial.

      Study objectives:

        -  Primary: event-free survival time following autologous stem cell transplantation with
           90Y-Ibritumomab tiuxetan and BuCyE high-dose chemotherapy in patients with relapsed,
           refractory, or high-risk B-cell non-Hodgkin's lymphoma

        -  Secondary: overall survival response rate toxicity of the treatment combination

      Treatment:

      Z-BuCyE Regimen

        -  Day 21: rituximab, 250 mg/m2, I.V.

        -  Day 14: rituximab, 250 mg/m2, I.V. 90Y-Ibritumomab tiuxetan, 0.4 mCi/kg, I.V.

        -  Day 7, 6, 5: busulfan 3.2 mg/kg I.V.

        -  Day 5, 4: etoposide 200 mg/m2 I.V. every 12 hours

        -  Day 3, 2: Cytoxan 50 mg/kg I.V.

        -  Day 0: autologous stem cell infusion
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2005</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event-free survival</measure>
    <time_frame>the time from stem cell infusion to failure or death from any cause</time_frame>
    <description>Three year event-free survival rate would be reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>from stem cell infusion to death of any cause or last follow-up</time_frame>
    <description>Three year overall survival would be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity of the treatment combination</measure>
    <time_frame>any toxicity due to study treatment during study period</time_frame>
    <description>Adverse events would be assessed and graded according to the National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE), version 3.0. And the frequency of each grade would be reported as case number and proportion.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Non-Hodgkin's Lymphoma</condition>
  <arm_group>
    <arm_group_label>Zevalin-BuCyE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>histologically confirmed, relapsed or refractory CD20 positive B-cell NHL including diffuse large B-cell, follicular, mantle cell, and Burkitt lymphomas.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zevalin-BuCyE</intervention_name>
    <description>rituximab (IV, 250 mg/m2 on days −21 and −14) single dose of 90Y-ibritumomab (IV, 0.4 mCi/kg on day −14) Busulfan (IV, 0.8 mg/kg every 6 h from day −7 to day −5) Cyclophosphamide (IV, 50 mg/kg on days −3 and −2) Etoposide (IV, 200 mg/m2 every 12 h on days −5 and −4) Autologous stem cells infusion on day 0</description>
    <arm_group_label>Zevalin-BuCyE</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed B-cell NHL in chemotherapy-sensitive relapse, in partial
             response to 1st line chemotherapy, or in complete response after 1st line chemotherapy
             with high IPI score at diagnosis

          -  Age &lt; 65 years old

          -  WHO performance status (PS) of 0-2

          -  ANC &gt; 1,500/mm3, platelet &gt; 100,000/mm3

          -  Cr &lt; 2.0 mg% or Ccr &gt; 50 mL/min

          -  Transaminase &lt; 3X upper normal value

          -  Bilirubin &lt; 2 mg/dL

          -  Life expectancy of at least 3 months

          -  Written informed consent

          -  Optimal harvest of autologous stem cells (CD34+ cells &gt; 5 million/kg plus 2 million/kg
             for back-up)

        Exclusion Criteria:

          -  Prior hematopoietic stem cell transplantation

          -  Prior RIT

          -  Prior external radiation to &gt; 25% of active bone marrow

          -  CNS involvement of non-Hodgkin's lymphoma

          -  Serious comorbid diseases

          -  HIV or HTLV-1 associated malignancy

          -  History of other malignant disease in the previous 5 years, except squamous cell or
             basal cell carcinoma of skin or stage I uterine cervical carcinoma or cervical
             carcinoma in situ

          -  Known hypersensitivity to murine antibodies/proteins

          -  Pregnant or breast feeding female patients, adults without effective contraception up
             to 12 months after RIT

          -  Persistent toxic side effects from prior therapy

          -  Prior biologic or immunotherapy less than 4 weeks prior to entry on this study

          -  Investigational drugs less than 4 weeks prior to entry on this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cheolwon Suh, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asan Medical Center, Departement of Internal Medicine, Division of Oncology</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <results_reference>
    <citation>Kang BW, Kim WS, Kim C, Jang G, Lee SS, Choi YH, Lee DH, Kim SW, Kim S, Ryu JS, Huh J, Lee JS, Suh C. Yttrium-90-ibritumomab tiuxetan in combination with intravenous busulfan, cyclophosphamide, and etoposide followed by autologous stem cell transplantation in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. Invest New Drugs. 2010 Aug;28(4):516-22. doi: 10.1007/s10637-009-9283-z. Epub 2009 Jun 23.</citation>
    <PMID>19547918</PMID>
  </results_reference>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 13, 2006</study_first_submitted>
  <study_first_submitted_qc>June 13, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 14, 2006</study_first_posted>
  <last_update_submitted>February 13, 2016</last_update_submitted>
  <last_update_submitted_qc>February 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Cheolwon Suh</investigator_full_name>
    <investigator_title>ASCT team</investigator_title>
  </responsible_party>
  <keyword>Zevalin</keyword>
  <keyword>B-cell non-Hodgkin's lymphoma</keyword>
  <keyword>autologous stem cell transplantation</keyword>
  <keyword>BuCyE regimen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

